Leveraging a strategic relationship from within our parent company JSR, KBI has partnered with Selexis SA, the global leader in mammalian cell line development, to provide the primary platform for our mammalian Cell Line Development services.
Selexis offers comprehensive and rapid solutions for the development of stable, high-yield, and clonal mammalian cell lines that are used in recombinant protein drug manufacturing.
With more than 100 partners worldwide, 100+ drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research.
Based on the SUREtechnology Platform™ and unique world-class expertise, Selexis SURE Cell Line Development™ Services significantly reduce the time, effort, and costs that are associated with the development of high-performance mammalian cell lines for therapeutic protein production (e.g., monoclonal antibodies, bi-specific monoclonal antibodies, growth factors, and enzymes).
KBI’s mAb and non-mAb process platforms provide titers of 2-10 g/L using 20 Selexis cell lines and KBI has performed GMP manufacturing with 10 Selexis cell lines allowing us to offer the most robust and fastest Gene to GMP service offering for the biopharmaceutical industry.